Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure by Mohiuddin, Syed et al.
                          Mohiuddin, S., Reeves, B., Pufulete, M., Maishman, R., Dayer, M., Macleod,
J., ... Hollingworth, W. (2016). A model-based cost-effectiveness analysis of
B-type natriuretic peptide-guided care in patients with heart failure. BMJ
Open, 6, [e014010]. DOI: 10.1136/bmjopen-2016-014010
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmjopen-2016-014010
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ Publishing
Group at http://dx.doi.org/10.1136/bmjopen-2016-014010. Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms.html
Model-based cost-effectiveness analysis
of B-type natriuretic peptide-guided
care in patients with heart failure
Syed Mohiuddin,1 Barnaby Reeves,2 Maria Pufulete,2 Rachel Maishman,2
Mark Dayer,3 John Macleod,1 Theresa McDonagh,4 Sarah Purdy,1 Chris Rogers,2
William Hollingworth1
To cite: Mohiuddin S,
Reeves B, Pufulete M, et al.
Model-based cost-
effectiveness analysis of
B-type natriuretic peptide-
guided care in patients with
heart failure. BMJ Open
2016;6:e014010.
doi:10.1136/bmjopen-2016-
014010
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2016-014010).
Received 23 August 2016
Revised 25 November 2016
Accepted 29 November 2016
For numbered affiliations see
end of article.
Correspondence to
Dr Syed Mohiuddin; syed.
mohiuddin@bristol.ac.uk
ABSTRACT
Objective: Monitoring B-type natriuretic peptide
(BNP) to guide pharmacotherapy might improve
survival in patients with heart failure with reduced
ejection fraction (HFrEF) or preserved ejection fraction
(HFpEF). However, the cost-effectiveness of BNP-
guided care is uncertain and guidelines do not
uniformly recommend it. We assessed the cost-
effectiveness of BNP-guided care in patient subgroups
defined by age and ejection fraction.
Methods: We used a Markov model with a 3-month
cycle length to estimate the lifetime health service
costs, quality-adjusted life years (QALYs) and
incremental net monetary benefits (iNMBs) of BNP-
guided versus clinically guided care in 3 patient
subgroups: (1) HFrEF patients <75 years; (2) HFpEF
patients <75 years; and (3) HFrEF patients ≥75 years.
There is no evidence of benefit in patients with HFpEF
aged ≥75 years. We used individual patient data meta-
analyses and linked primary care, hospital and
mortality data to inform the key model parameters. We
performed probabilistic analysis to assess the
uncertainty in model results.
Results: In younger patients (<75 years) with HFrEF,
the mean QALYs (5.57 vs 5.02) and costs (£63 527 vs
£58 139) were higher with BNP-guided care. At the
willingness-to-pay threshold of £20 000 per QALY, the
positive iNMB (£5424 (95% CI £987 to £9469))
indicates that BNP-guided care is cost-effective in this
subgroup. The evidence of cost-effectiveness of BNP-
guided care is less strong for younger patients with
HFpEF (£3155 (−£10 307 to £11 613)) and older
patients (≥75 years) with HFrEF (£2267 (−£1524 to
£6074)). BNP-guided care remained cost-effective in
the sensitivity analyses, albeit the results were sensitive
to assumptions on its sustained effect.
Conclusions: We found strong evidence that BNP-
guided care is a cost-effective alternative to clinically
guided care in younger patients with HFrEF. It is
potentially cost-effective in younger patients with
HFpEF and older patients with HFrEF, but more
evidence is required, particularly with respect to the
frequency, duration and BNP target for monitoring.
Cost-effectiveness results from trials in specialist
settings cannot be generalised to primary care.
INTRODUCTION
Heart failure (HF) is a major and growing
public health problem worldwide. HF is asso-
ciated with high risks of hospitalisation and
mortality, making it one of the most costly
conditions to manage. Global estimates indi-
cate that HF results in US$65 billion direct
care costs and US$43 billion in lost product-
ivity annually.1 In the UK, ∼500 000 people
live with HF,2 and this ﬁgure is likely to rise
as the population continues to age. Each
year, HF is the primary diagnosis in over
150 000 hospital episodes in the UK; many of
these are emergency admissions.2 Healthcare
costs increase sharply at the end of life and
are dominated by hospital care.3 The case
for many novel interventions in HF is based
on the expectation that the upfront costs will
be justiﬁed in the longer term by improved
Strengths and limitations of this study
▪ We combined recent individual patient data
meta-analyses of 2000 heart failure (HF) patients
participating in several randomised controlled
trials (RCTs) and evidence on the costs of care
from routine data in a cost-effectiveness model.
▪ We investigated the cost-effectiveness of B-type
natriuretic peptide (BNP)-guided care in sub-
groups of HF patients which were not reported in
the original RCT publications.
▪ We conducted sensitivity analyses to estimate
the uncertainty around our results and identify
patient subgroups where further evidence is
needed.
▪ We used a simplified model structure as the
majority of RCTs do not measure or report
changes in functional status at follow-up.
▪ None of the RCTs provided evidence on utility
scores; hence, we used scores reported else-
where in the HF literature which may not be
representative of patients eligible for BNP
monitoring.
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patient outcomes and/or savings due to reduced
hospitalisations.4 5
Pharmacological treatment for HF includes ACE inhi-
bitors, angiotensin receptor blockers, β blockers and
mineralocorticoid receptor antagonists. Achieving
optimal pharmacotherapy for HF is challenging and
complicated by potential side effects such as renal
failure and hypotension. Emerging evidence suggests
that monitoring serum B-type natriuretic peptide (BNP)
biomarkers can guide pharmacotherapy and improve
survival.6 7 BNP is a neurohormone secreted primarily
from the left ventricle of the heart in response to
changes in pressure that occur when HF develops and
worsens. In 2010, clinical guidelines8 in England and
Wales recommended specialist monitoring of BNP in
patients recently admitted to hospital, but also called for
further research on cost-effectiveness. More recent
North American guidelines9 considered the value of
serial BNP measurement to be not well established.
Evidence on the cost-effectiveness of BNP-guided care in
HF includes economic evaluations conducted alongside
randomised controlled trials (RCTs)10 11 and model-
based analyses12–14 synthesising costs and outcomes over
the lifetime of patients.
We conducted a model-based cost-effectiveness analysis
of BNP-guided care in patients with HF. Our analysis
differs from previous economic evaluations in two ways.
First, we exploited recent individual patient data (IPD)
meta-analyses6 7 in estimating the relative effect of
BNP-guided care. Among the advantages of IPD
meta-analysis is the opportunity to investigate the (cost-)
effectiveness of BNP-guided care in subgroups of
patients which are not analysed consistently or not
reported in the original RCT publications. Second, we
used linked data from the Clinical Practice Research
Database (CPRD; http://www.cprd.com), Hospital
Episode Statistics (HES; http://www.hscic.gov.uk/
hesdata) and Ofﬁce for National Statistics (ONS; http://
www.ons.gov.uk) to inform key parameters of the model.
In particular, we used these data to estimate the
National Health Service (NHS) costs of care for patients
with HF who are stable and treated in primary care com-
pared with those who are admitted to hospital. Our
objective was to synthesise the evidence on the cost-
effectiveness of BNP-guided care in subgroups of the
recently hospitalised HF population deﬁned by age and
left ventricular ejection fraction (LVEF) status.
METHODS
Overview of the model
We compared specialist-led BNP-guided care with
specialist-led clinically guided care in recently hospita-
lised patients with HF with a reduced ejection fraction
(HFrEF) or preserved ejection fraction (HFpEF). Two
RCTs15 16 included a third arm where usual care was
provided by a primary care physician, but we focused on
specialist-led care in common with the IPD
meta-analyses of RCTs.6 7 We used a simple Markov
process consisting of two health states: Alive and Dead
(ﬁgure 1), which is similar to the structure of a previous
cost-effectiveness model that was used to develop NICE
clinical guidelines on the management of HF8 and later
updated with additional RCTevidence.14
We tracked the probabilities of death (dt) and hospi-
talisation (ht), which varied with time in the model. We
did not model the interaction between the number of
hospitalisations and the subsequent risk of death. This
was a pragmatic decision as RCTs do not report mortal-
ity conditional on the number of hospitalisations. We
chose a cycle length of 3 months to track changes in out-
comes and resource use, as BNP was monitored every
3 months during follow-up in a number of RCTs16–18
and mortality differences have emerged by 3 months in
IPD meta-analyses.6 7 We assumed that transitions
between health states occur halfway through each cycle.
We estimated the average NHS costs and
quality-adjusted life years (QALYs) of a hypothetical
cohort of 1000 patients over their lifetime. Recent IPD
meta-analyses of RCTs6 7 have explored the relative
effectiveness of BNP-guided care in subgroups of the
recently hospitalised HF population deﬁned by age
(<75/≥75 years) and LVEF (≤45%/>45%) status. The
evidence that BNP-guided care is effective is strongest in
younger patients (<75 years) and in those with HFrEF.
However, there is no evidence to suggest that
BNP-guided care is beneﬁcial in older patients
(≥75 years) with HFpEF (HR 1.56 (95% CI 0.90 to
2.70)).6 Therefore, we estimated the cost-effectiveness of
BNP-guided care in three patient subgroups: (1) HFrEF
patients <75 years; (2) HFpEF patients <75 years; and
(3) HFrEF patients ≥75 years. Based on data from the
IPD meta-analysis,6 we used the mean ages of 65 and
81 years at the inception of treatment for the age-
subgroups <75 and ≥75 years, respectively. We tracked
outcomes for a period of 30 years for the age-subgroup
<75 and 15 years for the age-subgroup ≥75 years. This
equated for both strategies that more than 99% of
patients analysed have died.
We calculated QALYs by multiplying the health state
utility score by the time spent in that state.19 Costs and
QALYs were discounted at an annual rate of 3.5%.20 We
estimated the cost-effectiveness of BNP-guided care
based on the incremental net monetary beneﬁt (iNMB):
iNMB¼l ðQALYsBNPguided QALYsclinically guidedÞ
 ðCostBNPguided  Costclinically guidedÞ
Figure 1 Markov model of disease progression.
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where λ represents the maximum amount that the NHS
is ‘willing to pay’ to gain one QALY. We used the lower
NICE threshold (λ=£20 000) in calculating iNMB.21 An
iNMB value >0 would indicate that BNP-guided care is
cost-effective. We present cost-effectiveness acceptability
curves (CEACs) to demonstrate how the NHS
willingness-to-pay threshold affects the probability that
BNP-guided care is considered cost-effective.22 We also
present incremental cost-effectiveness ratios (ICERs).
Model parameters
We used four sets of parameters (tables 1 and 2): (1)
baseline probabilities of hospitalisation or death in the
clinically guided group; (2) relative treatment effects
(hazard ratios (HRs) and relative risks (RRs)), which
determine how the baseline probabilities differ in the
BNP-guided group; (3) utilities, which represent the
health-related quality of life of patients in each state;
and (4) NHS costs incurred in each state. The sources
of these data are described below.
Baseline probabilities: mortality
We used routinely collected CPRD-ONS linked data
from April 2005 up to the censoring date of April 2014,
including 52 122 patients with a HF hospital admission
(identiﬁed by ICD-10 diagnosis code), to estimate the
monthly mortality rate in clinical practice in the absence
of BNP-guided care. The mean (SD) age of the patients
at admission was 77.9 (12) years, and 49% were female.
This allowed us to estimate survival over a longer time
period than is available from RCTs. We excluded
patients who died in hospital or within 7 days of dis-
charge, as they would be unlikely to be eligible for
BNP-guided care, and a small minority who had fre-
quent BNP testing indicating that they were already
receiving BNP-guided care. Time between discharge
from ﬁrst HF admission to all-cause mortality and all-
cause rehospitalisation were calculated. Parametric sur-
vival models (assuming an Exponential distribution and
a Weibull distribution) were ﬁtted to the data ﬁtting age
(dichotomised into <75 and ≥75 years) to obtain esti-
mates of age-speciﬁc all-cause hazard rates. These sur-
vival analyses were carried out in Stata V.14.0. In our
primary analyses, we used the exponential hazard rate of
0.009 to estimate survival for younger patients for the
ﬁrst 8 years of the model. In a sensitivity analysis (SA1),
we used the Weibull hazard rate of 0.017 together with
the ancillary parameter estimate of 0.842 to estimate sur-
vival for younger patients for the ﬁrst 8 years of the
model.
Beyond the initial period, we used age-speciﬁc and
sex-speciﬁc ONS UK life-tables23 to estimate survival,
assuming that two-thirds of patients were male7 and
inﬂating population mortality for the HF population
using a RR derived from an observational study.24 van
Jaarsveld et al24 report 32% survival at 7-year for 293 inci-
dent HF cases diagnosed in the Netherlands between
1993 and 1998, compared with 70% survival among 586
age and sex-matched controls without HF. These 7-year
survival probabilities were converted to 3-monthly sur-
vival probabilities. The majority of patients recruited to
trials had HFrEF. After adjusting for age, gender and
other covariates, mortality has been demonstrated to be
lower in patients with HFpEF.25 31 Therefore, we
adjusted survival in the HFpEF subgroup evaluated in
our model, using results from a cohort of more than
6500 patients hospitalised for HF which reported an
adjusted 1-year mortality RR of 1.25 (95% CI 1.12 to
1.41) in patients with HFrEF versus HFpEF.25
Relative effects: mortality
We used an IPD meta-analysis to estimate the relative
effect of BNP-guided care on survival. Brunner-La Rocca
et al6 analysed seven RCTs in patients (n=1580) with
HFrEF and four RCTs in patients (n=296) with HFpEF.
In younger patients (<75 years), they found the strongest
evidence of a beneﬁcial effect of BNP-guided care
among patients with HFrEF (HR 0.68 (95% CI 0.48 to
0.96); n=881), while the evidence was weaker for
younger patients with HFpEF (HR 0.76 (0.29 to 1.96);
n=96). In older patients (≥75 years) with HFrEF, the evi-
dence was inconclusive (HR 0.87 (0.65 to 1.16); n=850),
but did not exclude the possibility of a clinically import-
ant effect.
Long-term follow-up is unavailable for most RCTs. In
the TIME-CHF RCT,32 BNP-guided care ceased at
18 months; over a 5-year follow-up period, the study
found a non-signiﬁcant trend for improved survival in
younger HFrEF patients with treatment guided by BNP
(HR 0.62 (0.37 to 1.03)). Very few patients were
followed-up for the full 5 years. In our primary analyses,
we assumed that the relative effect of BNP-guided care
would end after 4 years. However, it is plausible that
BNP-guided care becomes ineffective or less effective
before 4 years if, for example, compliance with care
decreases or the efﬁcacy of care decreases with age.
Equally, the relative effect may extend beyond 4 years.
To test the importance of this assumption, we per-
formed sensitivity analyses assuming that the relative
effect and cost of BNP-guided care cease at 2 years
(SA2) or that the relative effect extends for the lifetime
of patients (SA3).
Baseline probabilities and relative effects: hospitalisation
In the clinically guided group, we used survival analysis
of CPRD-ONS linked data, as described earlier, to esti-
mate the monthly hazard rate of all-cause hospitalisa-
tion. We then applied this hazard rate throughout the
lifetime of patients in the model. Neither Troughton
et al7 nor Brunner-La Rocca et al6 reported HRs for all-
cause hospitalisation stratiﬁed by LVEF status. In the
absence of evidence, to estimate the relative effect of all-
cause hospitalisation in the BNP-guided group, we used
a HR of 0.94 (0.84 to 1.07) for patients with any type of
HF as reported in an IPD meta-analysis by Troughton
et al.7 We modelled all-cause hospitalisation in our
Mohiuddin S, et al. BMJ Open 2016;6:e014010. doi:10.1136/bmjopen-2016-014010 3
Open Access
group.bmj.com on January 9, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
analyses. This is consistent with our focus on all-cause
mortality and allows for the possibility that savings
through reduced HF readmissions might be partially
offset by more admissions for concomitant disorders or
side effects of more intensive HF pharmacotherapy.
Cohort data comparing patients with HFrEF versus
HFpEF suggest that, after adjustment for covariates, there
is negligible difference in the risk of all-cause hospitalisa-
tion at 1 year.25 Therefore, we used the same risk of all-
cause hospitalisation for patients with HFrEF and HFpEF.
Cost parameters
We included the costs of: (1) BNP and renal testing; (2)
BNP-related uptitration of pharmacotherapy; (3)
unscheduled outpatient appointments; (4) managing
patients with HF in the community; and (5) treating
patients with HF in hospital.
The cost of a BNP blood test is £15–25.29 We used the
top end of this range to include the costs of additional
renal function tests. We tested the sensitivity of model
results to a 50% decrease (SA4) and 50% increase (SA5)
in the cost of BNP testing. Cumulative costs depend on
the frequency and duration of BNP monitoring. Based
on several RCTs,16–18 we assumed 3-monthly BNP testing
and that costs of BNP testing and uptitration of medica-
tions would cease at 18 months.
There is mixed evidence of the effect of BNP-guided
care on drug usage. Some trials17 18 27 reported
Table 1 Transition probability parameters used in the model
Parameter Mean estimate Distribution Source
Baseline monthly hazard rate of all-cause mortality
for the first 8 years of the model (<75 years)
0.009 LN (−4.718, 0.012 SE) CPRD-ONS
HR (≥75 vs <75 years) of all-cause mortality for the
first 8 years of the model
2.801 LN (1.030, 0.014 SE) CPRD-ONS
3-monthly risk of all-cause mortality in general
population
Age variant Fixed ONS23
RR (HF patients vs general population) of all-cause
mortality
3.14 β (199, 94)* HF/
β (176, 410)* gen. pop.
van Jaarsveld et al24
RR (HFpEF patients vs HFrEF patients) of
all-cause mortality
0.78 β (766, 2865)* HFpEF/
β (584, 1621)* HFrEF
Nichols et al25
BNP HR of all-cause mortality for HFrEF patients
<75 years
0.68 LN (−0.386, 0.177 SE) Brunner-La Rocca et al6
BNP HR of all-cause mortality for HFpEF patients
<75 years
0.76 LN (−0.274, 0.487 SE) Brunner-La Rocca et al6
BNP HR of all-cause mortality for HFrEF patients
≥75 years
0.87 LN (−0.139, 0.148 SE) Brunner-La Rocca et al6
Baseline monthly hazard rate of all-cause
hospitalisation (<75 years)
0.066 LN (−2.711, 0.008 SE) CPRD-ONS
HR (≥75 vs <75 years) of all-cause hospitalisation 1.248 LN (0.222, 0.010 SE) CPRD-ONS
BNP HR of all-cause hospitalisation 0.94 LN (−0.062, 0.062 SE) Troughton et al7
*β parameters were determined empirically.
CPRD, Clinical Practice Research Database; HES, Hospital Episode Statistics; LN, log normal; ONS, Office for National Statistics; RR,
relative risk.
Table 2 Utility, resource use and cost parameters used in the model
Parameter Mean estimate Distribution Source
HF utility score when hospitalised 0.66 (0.26 SD) β (7321, 3772)* Reed et al26
HF utility score when not-hospitalised 0.77 (0.23 SD) β (7978, 2383)* Reed et al26
Duration of hospitalisation (days) 13.21 (0.39 SE) γ (1148.29, 0.01)* CPRD-HES3
3-monthly cost when hospitalised (age <75 years) £9104 (349.61 SE) γ (678.06, 13.43)* CPRD-HES3
3-monthly cost when not-hospitalised (age <75 years) £682 (23.72 SE) γ (827.17, 0.82)* CPRD-HES3
3-monthly cost when hospitalised (age ≥75 years) £8057 (192.77 SE) γ (1746.96, 4.61)* CPRD-HES3
3-monthly cost when not-hospitalised (age ≥75 years) £569 (14.52 SE) γ (1536.51, 0.37)* CPRD-HES3
Clinically guided unscheduled outpatient visits (24 months) 1.10 (0.13 SE) γ (71.60, 0.02)* PRIMA27
BNP-guided unscheduled outpatient visits (24 months) 1.40 (0.14 SE) γ (94.52, 0.02)* PRIMA27
BNP-guided additional cost of medications (18 months) £58.32 (6.20 SE) γ (88.42, 0.66)* TIME-CHF11
Unit cost of an outpatient visit £123 Fixed DoH28
Unit cost of a BNP test £25 Fixed NICE29
*β and γ parameters were determined using the methods of moments described elsewhere.30
CPRD, Clinical Practice Research Database; HES, Hospital Episode Statistics.
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increases in doses of some drugs in the BNP-guided
arm, whereas others16 33 34 do not. In the TIME-CHF
RCT economic evaluation,11 medication costs were 12%
higher (US$747 vs US$668; p=0.04 (2006 values)) in the
BNP-guided arm over an 18-month follow-up period. We
used this incremental cost (US$79), inﬂated to 2013/
2014 values and converted to £58.32, to estimate the
potential increase in medication costs. BNP-guided care
might also increase the number of unscheduled out-
patient visits due to increased side effects of pharmaco-
therapy; however, most trials do not report this outcome.
The PRIMA trial27 found inconclusive evidence of a
higher mean number of unscheduled outpatient
appointments in the BNP-guided arm than the clinically
guided arm at 2 years (1.4 vs 1.1; p=0.06). We used this
estimate and a unit cost of £123 per outpatient
appointment.28
We used CPRD-HES linked data,3 to estimate the age-
subgroup speciﬁc mean costs (table 2) of NHS care
during a 3-month period for patients hospitalised with
HF at some point during that period and patients not
hospitalised during that period. In brief, we identiﬁed
1555 patients in England who died with HF in 2012/
2013. Of these patients, 47.4% were female and 60.2%
had HF diagnosis in the last 2 years, and the mean (SD)
age at death was 83 (10) years. We estimated the cost of
medications, primary and hospital healthcare during
each 90-day period in the 5 years before death. These
analyses found no strong evidence of additional NHS
costs for patients with left ventricular dysfunction (mean
incremental cost: £234 (95% CI −£113 to £580)), and
therefore, we used the same estimates in HFrEF and
HFpEF subgroup analyses. All costs were estimated in
2013/2014 GBP£.
Utility parameters
We conducted a structured search of MEDLINE and
EMBASE to identify studies which reported utility scores,
preferably using the EQ-5D, in patients with HF strati-
ﬁed by hospitalisation status. We included keywords and
medical subject headings for HF, utilities and QALYs.
The ASCEND-HF multinational trial26 reports utility
scores among more than 6000 patients hospitalised with
acute decompensated HF and randomised to nesiritide
or placebo. EQ-5D-3L scores were collected at baseline,
24 hours, discharge and 30 days. In the placebo arm, the
mean (SD) EQ-5D-3L utility scores increased from 0.55
(0.29) at admission to 0.66 (0.26) at 24 hours and 0.77
(0.23) at discharge. EQ-5D-3L scores did not change
substantially postdischarge; 0.74 (0.25). We assumed that
the utility score at 24 hours was representative of the
average utility score (Uh) of patients with acute decom-
pensation during hospitalisation and that the utility score
at discharge was representative of average utility score
(Unh) among patients with stable HF not-hospitalised. We
assumed that these two utility values were independent of
monitoring strategy; therefore, any improvement in
quality of life from BNP-guided care in the model is the
result of reducing the risk of readmission. Evidence from
most RCTs,16 17 27 34 which have measured quality of
life, indicates no difference between patients with
BNP-guided versus clinically guided care. We assumed
that utility values did not decline with age or differ by
LVEF status.
Using the CPRD-HES linked data on the 1555 patients
described above, we estimated that patients with HF hos-
pitalised would have a mean (SE) length of stay of 13.21
(0.39) days within a 3-month cycle. Therefore, the mean
QALYs gained during a 3-month (ie, 91.31-day) cycle
which included a hospitalisation (QALYsh) and non-
hospitalisation (QALYsnh) are:
QALYsh ¼ ððPh  13:21UhÞ þ ðPnh  ð91:31 13:21Þ
UnhÞÞ=365:25
QALYsnh ¼ ðPnh  91:31UnhÞ=365:25
where Ph represents the proportion of hospitalised
patients at each cycle and Pnh represents the proportion
of not-hospitalised patients at each cycle.
Probabilistic sensitivity analysis
We used probabilistic sensitivity analysis (PSA) to esti-
mate 95% CIs around the results.35 Monte Carlo simula-
tion was used to draw a randomly selected estimate of
each model parameter from the distribution described
in tables 1 and 2 and calculate the iNMB. β distributions
were used to represent the uncertainty in the probability
and utility parameters because these values are typically
bounded at zero and one. Log-normal distributions were
used to estimate uncertainty in hazard rates and ratios. γ
distributions were used to represent the uncertainty in
the cost parameters because these values are constrained
to be non-negative, but can have skewed distributions.
We used 10 000 iterations to empirically estimate the
uncertainty surrounding the mean iNMB. We built the
model in Microsoft Excel, and programmed in Visual
Basic for Applications.
RESULTS
Our results indicate that BNP-guided care is more costly,
but also more effective, than clinically guided care over
the lifetime of younger patients (<75 years) with HFrEF
(table 3). The median survival is longer in patients with
BNP-guided care (7.75 vs 6.43 years; ﬁgure 2). The dif-
ference in the mean QALYs is smaller (5.57 vs 5.02;
table 3), reﬂecting the imperfect health of survivors and
the discounting of health gained in future years.
Lifetime costs are estimated to be higher in patients
with BNP-guided care (£63 527 vs £58 139; table 3) as
the potential for decreased hospitalisation is more than
offset by BNP testing and the costs of healthcare during
the extended survival period. The positive iNMB statistic
(£5424 (95% CI £987 to £9469); table 3) indicates that
BNP-guided care is cost-effective in this subgroup. The
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CI is broad, primarily due to the uncertainty around the
relative effect of BNP-guided care on mortality; however,
it does not include zero. There is a high probability
(0.99) that BNP-guided care is cost-effective in this sub-
group at the willingness-to-pay threshold of £20 000 per
QALY (ﬁgure 3).
The evidence of cost-effectiveness of BNP-guided care
is less strong for the subgroup of younger patients with
HFpEF. The median survival (9.54 vs 8.43 years; ﬁgure
2) and mean QALYs (6.23 vs 5.86; table 3) are higher
in patients with BNP-guided care. However, the iNMB
is relatively small with a broad CI spanning zero (£3155
(−£10 307 to £11 613); table 3). Nevertheless, there is a
relatively high probability (0.75) that BNP-guided care is
cost-effective in this subgroup at the willingness-to-pay
threshold of £20 000 per QALY (ﬁgure 3).
There is some evidence that BNP-guided care has the
potential to be cost-effective among older patients
(≥75 years) with HFrEF. However, life expectancy
(ﬁgure 2) is much shorter in this subgroup than in
younger patients; and therefore, the estimated gain in
QALYs (2.39 vs 2.20; table 3) and the iNMB are small,
and the CI spans zero (£2267 (−£1524 to £6074);
table 3). There is a relatively high probability (0.88)
that BNP-guided care is cost-effective in this subgroup at
the willingness-to-pay threshold of £20 000 per QALY
(ﬁgure 3).
Sensitivity analyses
The estimated value of BNP-guided care is sensitive to
assumptions about its sustained effect (table 4). If the
relative effect and cost of BNP-guided care cease at
2 years (SA2), the incremental costs and QALYs are
smaller. However, the conclusion that BNP-guided care
is probably cost-effective in younger patients with HFrEF
does not change (iNMB: £2834 (£284 to £5079)). If the
beneﬁt of BNP-guided care is sustained over patient life-
times (SA3), the estimated cost-effectiveness (iNMB:
£12 275 (£1090 to £24 289)) increases greatly.
Substituting a Weibull survival model (SA1) and
Table 3 Cost-effectiveness results in three patient subgroups
Clinically guided BNP-guided
Subgroup Cost* QALYs* Cost* QALYs* iNMB† (95% CI) ICER*
HFrEF patients <75 years £58 139 5.02 £63 527 5.57 £5424 (£987 to £9469) £9840
HFpEF patients <75 years £67 694 5.86 £71 097 6.23 £3155 (−£10 307 to £11 613) £9066
HFrEF patients ≥75 years £26 093 2.20 £27 676 2.39 £2267 (−£1524 to £6074) £8123
*Deterministic analysis.
†Probabilistic sensitivity analysis.
ICER, incremental cost-effectiveness ratio; iNMB, incremental net monetary benefit.
Figure 2 Survival curves for the three patient subgroups.
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changing the unit cost of the BNP test (SA4, SA5) had
minimal impact on conclusions about cost-effectiveness.
DISCUSSION
Principal findings
We found strong evidence that BNP-guided care is a
cost-effective alternative to clinically guided care in
younger patients (<75 years) recently hospitalised with
HFrEF. This conclusion holds even if the impact of
BNP-guided care on mortality is assumed to dissipate
after 2 years. The upfront costs of BNP-guided care are
justiﬁed by improvements in survival. There is no strong
evidence that costs of BNP-guided care will be offset by
fewer hospitalisations. We also found that BNP-guided
care has the potential to be cost-effective in younger
patients with HFpEF and older patients (≥75 years) with
HFrEF. However, more evidence is required before any
ﬁrm conclusions can be drawn in these patient sub-
groups. Relatively, few younger patients with HFpEF are
included in RCTs and, therefore, conclusions about cost-
effectiveness in this subgroup are tentative. Although a
larger number of older patients with HFrEF have partici-
pated in RCTs, the effectiveness of BNP-guided care
appears to be attenuated in this subgroup and cost-
effectiveness remains unproven.
Strengths and weaknesses
Our analyses used estimates from IPD meta-analyses6 7
of ∼2000 patients participating in several RCTs. We
investigated the cost-effectiveness of BNP-guided care in
subgroups of patients which were not reported in the
Figure 3 Cost-effectiveness acceptability curves for each of the three patient subgroups in the B-type natriuretic peptide
(BNP)-guided care. The circles represent the willingness-to-pay thresholds beyond which the BNP-guided care is most likely to
be cost-effective.
Table 4 Sensitivity analyses based on heart failure with reduced ejection fraction patients <75 years
Clinically guided BNP-guided
Sensitivity analysis (SA) Cost* QALYs* Cost* QALYs* iNMB† (95% CI) ICER*
SA1: Weibull form of survival function £59 025 5.10 £64 939 5.69 £5775 (£936 to £10 073) £9983
SA2: BNP-guided care cease at 2 years £58 139 5.02 £61 327 5.33 £2834 (£284 to £5079) £10 387
SA3: BNP-guided care continue for lifetime £58 139 5.02 £71 197 6.29 £12 275 (£1090 to £24 289) £10 274
SA4: Low cost (£12.5) of a BNP test £58 139 5.02 £63 458 5.57 £5453 (£993 to £9467) £9714
SA5: High cost (£37.5) of a BNP test £58 139 5.02 £63 596 5.57 £5303 (£800 to £9328) £9966
*Deterministic analysis.
†Probabilistic sensitivity analysis.
ICER, incremental cost-effectiveness ratio; iNMB, incremental net monetary benefit.
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original RCT publications. Within each subgroup, the
meta-analysis preserves the original randomisation;
however, comparison of effect sizes between subgroups
may be confounded by study as some RCTs contribute
no data to some subgroups (eg, HFpEF).36 In most
RCTs, participants and clinicians were not blind to
group allocation, introducing the possibility of perform-
ance bias including better ancillary care in the
BNP-guided care group unrelated to BNP levels. We con-
ducted the PSA to estimate the uncertainty around our
estimates, which allowed us to identify patient subgroups
where further evidence is needed. We had insufﬁcient
data to estimate the correlation between model para-
meters which would have allowed a better estimate of
the uncertainty in our model results. Deterministic sensi-
tivity analyses allowed us to demonstrate that plausible
changes to assumptions about the sustained beneﬁt of
BNP-guided care do not alter conclusions that
BNP-guided care is cost-effective in younger patients
with HFrEF, but are inﬂuential in estimating the abso-
lute health beneﬁt for patients.
We used a highly simpliﬁed two-state Markov model to
track costs and patient outcomes. A model tracking dys-
function (eg, NYHA class) and the probability of hospi-
talisation and death conditional on dysfunction would
provide a more realistic representation of disease pro-
gression and the increase in healthcare costs at the end
of life. For example, Ieva et al37 used routine data to
model the decrease in time to readmission with each
successive admission and the association between age,
gender and readmission. The simplicity of our model
might lead to poor estimates of cost-effectiveness if
BNP-guided care has a large effect on functional decline
among survivors. However, several RCTs16 17 27 34
provide little evidence of improved quality of life among
survivors with BNP-guided care. None of the RCTs pro-
vided evidence on utility scores; therefore, we used
scores reported elsewhere in the HF literature which
may not be representative of patients eligible for BNP
monitoring. Our analyses focus on costs to the health
service, rather than wider costs falling on social care or
patients and families. BNP-guided care will be more cost-
effective if, for example, it results in fewer admissions to
residential or nursing homes.
Comparisons with other studies
The TIME-CHF RCT economic evaluation11 in HFrEF
patients (mean age 76 years) estimated higher costs (US
$384 (−$3462 to $4803); after excluding residential
costs) and higher QALYs (0.05 (−0.02 to 0.11)) in
patients with BNP-guided care at 18 months.11 The
authors concluded that BNP-guided care had a high
probability of being cost-effective, but noted that this
probability was lower in older patients. Laramée et al14
published the only UK-based economic model of
BNP-guided care, developing previous work included in
the NICE HF clinical guidelines.8 Their analysis is based
on aggregate, rather than individual patient, data from
six RCTs. The structure of their model is similar to ours,
but the key model parameter estimates differ. They con-
clude that BNP-guided care is most probably cost-
effective in patients with HFrEF and in younger patients
with HF from any cause. An acknowledged limitation of
their analysis is that they could not explore cost-
effectiveness in patients with HFpEF.
Implications for clinicians and policymakers
Although BNP tests are relatively cheap, there will be
logistical and ﬁnancial challenges to routine implemen-
tation in the UK. If, as in most RCTs, BNP monitoring is
conducted in an outpatient setting by physicians skilled
in HF care, existing gaps between guidelines and
current practice need to be bridged; many patients in
the UK do not receive cardiology or HF nurse
follow-up.38 Cost-effectiveness results based on trials of
BNP monitoring by specialists in outpatient settings
cannot be simply generalised to primary care. The
BATTLESCARRED RCT16 compared BNP-guided and
clinically guided care in a specialist clinic with usual
primary care and found that usual primary care resulted
in inferior survival at 1 year. The SIGNAL-HF RCT34
which recruited patients with stable HF in primary care
found no important improvements in clinical outcomes
for patients with BNP-guided care.
Another hurdle to implementing BNP-guided care is
that there is little consensus on the optimal frequency,
duration and BNP target for monitoring. Developments
in medical therapy will also inﬂuence the use of moni-
toring. New drugs, such as Entresto, which inhibits
neprilysin and increases the levels of natriuretic pep-
tides, would require different monitoring strategies.39
However, NT-proBNP will remain a useful biomarker in
this situation.40
Unanswered questions and future research
Most uncertainty in our model is caused by wide CIs sur-
rounding the relative effect of BNP-guided care, particu-
larly in patient subgroups not well represented in RCTs.
The ongoing GUIDE-IT trial41 will be vital in providing
better evidence in older patients with HFrEF and in sup-
porting or refuting existing evidence from smaller RCTs
for younger patients with HFrEF. Larger numbers of
RCT participants will enable more detailed exploration
of other patient subgroups. For instance, comorbidities
may explain the lower efﬁcacy of BNP-guided care in
older patients.6 The potential for harm from aggressive
medication titration among elderly patients or those
with signiﬁcant renal dysfunction needs to be explored
further before ﬁrm conclusions can be drawn in these
patient groups.42
Despite the high prevalence of HF, there is surpris-
ingly little research on the economic impact on health
systems, families and societies.3 Future research, particu-
larly on residential care needs, informal care needs and
productivity losses due to HF, is needed in order to
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better judge the economic case for interventions like
BNP-guided care.
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